Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

Exclusion Criteria

• •Pregnancy, planned pregnancy (within the study period) or women currently breastfeeding.
• •Subjects with weight changes greater than 20% over the past 3 months.
• •Subjects planning a significant change in diet or exercise levels.
• •Subjects already consuming more than 1.5 g per day of Eicosapentaenoic Acid (EPA) or Docosahexaenoic Acid (DHA) in any form.
• •Subjects taking supplements or medications that affect lipoproteins for at least the past six weeks including fish oil supplements, bile-acid sequestrants, plant sterol supplements, fibrates, statins or Niacin.
• •Subjects diagnosed with cancer or IBD, or that have taken diarrhea inhibitors, laxatives or prebiotics in the week before stool sampling (optional), or antibiotics within 3 months before sampling.
• •Subjects taking daily aspirin or other anti-platelet or anti-coagulants agents (Plavix).
• •History of prostate Cancer
• •Subjects with known bleeding disorders (for example, Hemophilia)
• •Known sensitivity or allergy to fish, shellfish or omega-3 fatty acids supplements
• •Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other conditions that could affect intestinal fat absorption
• •Subjects with any acute and life-threatening condition, such as prior sudden cardiac arrest, acute myocardial infarction (last three months), stroke, embolism
• •Liver enzymes (aspartate aminotransferase (AST) or alanine transaminase (ALT)) levels above 3x upper limit of normal
• •Subjects initiating new medications or patients on multiple medications may also be excluded according to investigator discretion
• •Subjects previously diagnosed with cardiac dysrhythmia
• •Subjects with clinically diagnosed hepatic disease (including but not limited to auto immune disease, hepatitis and cirrhosis)
• •Anticipated surgery during the study period
• •Blood donation in the last 2 weeks or planned blood donation during the study
• •Subjects requiring regular transfusions for any reason
• •Subjects may also be excluded for any reason that may compromise their safety or the accuracy of research data.
• •Subjects being treated with tamoxifen, estrogens, or progestins that have not been stable for \>4 weeks.
• •Subjects that thyroid stimulating hormone (TSH) levels are greater than 1.5 x Upper Limit of Normal (ULN) or clinical evidence of hypothyroidism